![DSpace logo](/jspui/image/logo.gif)
Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13678
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chitkara, Deepak | - |
dc.contributor.author | Mittal, Anupama | - |
dc.date.accessioned | 2024-01-05T07:01:48Z | - |
dc.date.available | 2024-01-05T07:01:48Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.uri | https://www.future-science.com/doi/full/10.4155/tde-2017-0016 | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13678 | - |
dc.description.abstract | Glioblastoma multiform (GBM) is the most devastating, highly aggressive astrocytic cell neoplasm having a median survival of 12–15 months and a 5-year survival rate of <3% [1]. Surgery along with radiation therapy and/or chemotherapy is the standard treatment strategy for primary brain tumors wherein, the survival advantages are only palliative. Despite clinical and technological advances, a cure for GBM remains elusive due to its diffuse infiltrative pattern of growth (hindering complete surgical resection), cytogenetic heterogeneity (limiting the use of pathway-specific targeted agents) and location (need to cross the blood–brain barrier [BBB]). Temozolomide (TMZ) is the first-line chemotherapy for GBM used in conjunction with radiotherapy or as a single agent for maintenance therapy [1]. It is an imidazotetrazine class DNA alkylating agent that methylates guanine and adenine bases of DNA leading to DNA double-strand breaks, cell cycle arrest and eventual cell death [1]. An autophagy induction leading to cell death has also been reported as a putative mechanism of action of TMZ in cancer cells and GBM patients [2]. Looking at the current therapy for GBM, there is still an unmet medical need resulting due to its inefficient delivery of TMZ to the cancer tissue. Only a modest activity is seen for TMZ, particularly in high-grade gliomas, which is further limited by the development of resistance leaving no viable therapeutic option for recurrent glioblastoma [3]. Further, TMZ is an unstable molecule that undergoes rapid hydrolysis and has significant dose-limiting hematological toxicity that prevents dosage increase [1]. Currently, TMZ is given orally or intravenously (TEMODAR®) at a dose of 75 mg/m2 concomitant with radiotherapy for 49 days followed by 150 mg/m2 (cycle 1) and 200 mg/m2 (cycle 2–6) as a maintenance dose. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Future Science Group | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | Cancer | en_US |
dc.subject | Temozolomide | en_US |
dc.subject | Glioblastoma multiforme | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject | Polymer drug | en_US |
dc.title | New strategies for cancer management: how can temozolomide carrier modifications improve its delivery? | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.